13D Filing: Bain Capital Life Sciences Fund, L.p. and Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Page 10 of 12

Page 10 of 12 – SEC Filing


CUSIP No. 253031108 13D Page
10

of 12

Termination

The Registration Rights Agreement will terminate on the earlier to occur of (i) the date on which no Investor holders any Registrable Securities and
(ii) the date on which the Issuer is no longer subject to the reporting requirements of Section 13 or 15(d) of the Act.

Item 7. Material to be Filed as Exhibits
Exhibit A Joint Filing Agreement
Exhibit B Redeemable Convertible Preferred Stock Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Issuers Form 8-K filed March 30, 2017)
Exhibit C Certificate of Designation (incorporated by reference from Exhibit 3.1 to the Issuers Form 8-K filed March 30, 2017)
Exhibit D Registration Rights Agreement (incorporated by reference from Exhibit 10.2 to the Issuers Form 8-K filed March 30, 2017)

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Page 10 of 12